2.1 Dosing Information

The recommended dosage of ZINBRYTA is 150 milligrams injected subcutaneously once monthly [see Dosage and Administration (2.3, 2.4)].

Instruct patients to inject a missed dose as soon as possible but no more than two weeks late. After two weeks, skip the missed dose and take the next dose on schedule. Administer only one dose at a time.

2.2 Important Administration Instructions

ZINBRYTA is for subcutaneous use only.

Train patients in the proper technique for self-administering subcutaneous injections using the prefilled autoinjector or syringe.

Thirty minutes prior to injection, remove ZINBRYTA from the refrigerator to allow the drug to warm to room temperature. Do not use external heat sources such as hot water to warm ZINBRYTA. Do not place ZINBRYTA back into the refrigerator after allowing it to warm to room temperature [see How Supplied/Storage and Handling (16.2)].

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ZINBRYTA is a colorless to slightly yellow, clear to slightly opalescent solution. Do not use ZINBRYTA if it is cloudy or there are visible particles.

Sites for injection include the thigh, abdomen, and back of the upper arm.

Use each prefilled autoinjector or syringe one time and then place in a sharps disposal container for disposal according to community guidelines [see How Supplied/Storage and Handling (16.3)].

2.3 Assessment Prior to Initiating ZINBRYTA

2.4 Laboratory Testing and Monitoring to Assess Safety after Initiating ZINBRYTA

Conduct the following laboratory tests at periodic intervals to monitor for early signs of potentially serious adverse effects:

5.1 Hepatic Injury

ZINBRYTA can cause severe liver injury, including autoimmune hepatitis and liver failure. Fatal cases have occurred. In controlled studies, serious drug-related hepatic injury occurred in 0.7% of ZINBRYTA-treated patients compared with 0.4% of AVONEX-treated patients (Study 1) and in 1.0% of ZINBRYTA-treated patients compared with no injury in placebo patients (Study 2). Across all clinical studies (controlled and open-label), serious drug-related hepatic injury occurred in 1.7% of ZINBRYTA-treated patients, with monthly monitoring of transaminases and total bilirubin. The incidence of discontinuation due to drug related hepatic injury was 5% in ZINBRYTA-treated patients and 4% in AVONEX-treated patients.

Across all clinical studies (controlled and open-label), 0.3% of ZINBRYTA-treated patients were diagnosed with autoimmune hepatitis. One fatal case of autoimmune hepatitis with acute liver failure occurred in a patient re-initiating ZINBRYTA after a planned 6 month treatment interruption period. This patient subsequently received two doses of ZINBRYTA in the presence of persisting alanine aminotransferase levels (ALT) more than 5 times the upper limit of normal (ULN).

Another case of acute liver failure occurred in a patient receiving ZINBRYTA in the postmarketing setting after 4 doses of ZINBRYTA, resulting in transplant and death. This patient had normal serum transaminase and total bilirubin levels 6 days prior to the last administration of ZINBRYTA. The patient was also receiving concomitant treatment with another drug known to be associated with hepatic injury [see Drug Interactions (7.1)].

5.2 Immune-Mediated Disorders

Treatment with ZINBRYTA increases the risk of immune-mediated disorders, including autoimmune disorders such as autoimmune hepatitis. Across all clinical studies (controlled and open-label), immune-mediated disorders occurred in 28% of patients on ZINBRYTA, the most common of which were skin reactions and lymphadenopathy. In the active-control study (Study 1), immune-mediated disorders were observed in 32% of ZINBRYTA-treated patients compared with 12% for AVONEX-treated patients. In Study 1, serious immune-mediated disorders were observed in 4% of patients treated with ZINBRYTA compared with less than 1% for AVONEX-treated patients. In the placebo-control study (Study 2), immune-mediated disorders were observed in 13% of ZINBRYTA-treated patients compared with 7% of placebo-treated patients. In Study 2, serious immune-mediated disorders were observed in 0.5% of ZINBRYTA-treated patients and in 0.5% of placebo-treated patients. In some cases, patients had concurrent or sequential occurring disorders while taking ZINBRYTA.

Some patients required invasive procedures for diagnosis (e.g., colonoscopy, liver biopsy, kidney biopsy, lung biopsy), hospitalization for fluid replacement or blood transfusion, or prolonged treatment with systemic corticosteroids or immunosuppressant drugs. Some of these events did not resolve after stopping ZINBRYTA during study follow-up.

Prescribers should be vigilant regarding emergent immune-mediated disorders. For suspected immune-mediated disorders, ensure adequate evaluation to confirm etiology or to exclude other causes. If a patient develops a serious immune-mediated disorder, consider stopping ZINBRYTA and refer the patient to an appropriate specialist for further evaluation and treatment.

5.3 ZINBRYTA REMS Program

ZINBRYTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ZINBRYTA REMS Program, because of the risks of hepatic injury including autoimmune hepatitis, and other immune-mediated disorders [see Warnings and Precautions (5.1, 5.2)].

Notable requirements of the ZINBRYTA REMS Program include the following:

• Prescribers must be certified with the program by enrolling and completing training.
• Patients must enroll in the program and comply with ongoing monitoring requirements [see Warnings and Precautions (5.1, 5.2)].
• Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive ZINBRYTA.

Further information, including a list of qualified pharmacies/distributors, is available at 1-800-456-2255.

5.4 Acute Hypersensitivity

ZINBRYTA can cause anaphylaxis, angioedema, and urticaria after the first dose or at any time during treatment. Discontinue and do not re-start ZINBRYTA if anaphylaxis or other allergic reactions occur [see Contraindications (4)].

5.5 Infections

ZINBRYTA increases the risk for infections. In controlled trials, infections occurred in 65% of ZINBRYTA-treated patients compared with 57% of AVONEX-treated patients (Study 1) and in 50% of ZINBRYTA-treated patients compared with 44% of patients taking placebo (Study 2). Serious infections occurred in 4% of ZINBRYTA-treated patients compared with 2% of AVONEX-treated patients (Study 1) and in 3% of ZINBRYTA-treated patients compared with none on placebo (Study 2).

The most common types of infections observed were upper respiratory tract infections, urinary tract infections and viral infections.

Cytomegalovirus (CMV) infections (hepatitis and pneumonia) occurred in ZINBRYTA-treated patients in clinical trials.

In clinical trials, cases of tuberculosis occurred in countries where tuberculosis is endemic. Evaluate high-risk patients for tuberculosis infection prior to initiating treatment with ZINBRYTA. For patients testing positive for tuberculosis, treat by standard medical practice prior to therapy with ZINBRYTA [see Dosage and Administration (2.3)].

Avoid initiating ZINBRYTA in patients with severe active infection until the infection is fully controlled. If serious infection develops, consider withholding treatment with ZINBRYTA until the infection resolves.

5.6 Depression and Suicide

Depression-related events occurred more frequently in patients receiving ZINBRYTA than in patients receiving AVONEX or placebo. In controlled trials, depression-related events occurred in 10% of ZINBRYTA-treated patients compared with 8% of AVONEX-treated patients (Study 1) and in 7% of ZINBRYTA-treated patients compared with 2% of patients taking placebo (Study 2). In Study 1, serious events related to depression, including suicidal ideation or suicide attempt, occurred in 0.4% of ZINBRYTA-treated patients and in 0.7% of AVONEX-treated patients. None occurred in Study 2 (placebo-controlled).

Administer ZINBRYTA with caution to patients with previous or current depressive disorders. Advise patients and/or caregivers to immediately report any symptoms of new or worsening depression and/or suicidal ideation to their healthcare provider.

If a patient develops severe depression and/or suicidal ideation, consider discontinuation of ZINBRYTA.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of ZINBRYTA cannot be directly compared with rates in clinical trials of other drugs and may not reflect the rates observed in practice.

In all controlled and uncontrolled trials performed in patients with relapsing multiple sclerosis, 2236 patients received ZINBRYTA for a total of 5214 person-years. Of these patients, 1576 received ZINBRYTA for at least 1 year, 1259 for at least 2 years, and 888 for at least 3 years. In the controlled studies, approximately 67% were female, 92% were Caucasian, and the mean age was 36 years at study entry.

In the active-controlled study (Study 1), 919 patients received ZINBRYTA (150 mg SQ, every 4 weeks) and 922 patients received AVONEX (interferon beta-1a 30 mcg IM, weekly) for a minimum of 2 years and up to 3 years, with 1952 person-years of exposure to ZINBRYTA; the median length of treatment was approximately 27 months. The adverse reactions from Study 1 are presented in Table 2.

In the placebo-controlled study (Study 2), 417 patients received ZINBRYTA with 423 person-years of exposure, of which 208 received 150 mg, and 204 received placebo every 4 weeks for up to 1 year; the median length of treatment was approximately 11 months. The adverse reactions from Study 2 are presented in Table 3.

The most common adverse reactions (incidence at least 5% and at least 2% higher incidence than comparator) that occurred in ZINBRYTA-treated patients were nasopharyngitis, upper respiratory tract infection, rash, influenza, dermatitis, oropharyngeal pain, bronchitis, eczema, and lymphadenopathy compared with AVONEX; and upper respiratory tract infection, depression, rash, pharyngitis, and increased alanine aminotransferase (ALT) compared with placebo.

The most common adverse reactions leading to discontinuation in up to 5% of patients treated with ZINBRYTA were hepatic events including elevations of serum transaminases and cutaneous events.

Patients were excluded from the clinical studies for abnormal laboratory values including hemoglobin, complete blood count with differential, serum transaminases, or serum creatinine. Patients were excluded if they had a history of seizure disorder or of having a seizure within 6 months of beginning the study, or suicidal ideation or severe depression within 3 months of beginning the study. During Study 1, concomitant use of ZINBRYTA with the hepatotoxic drugs valproic acid, carbamazepine, lamotrigine, phenytoin, isoniazid, and propylthiouracil was not permitted except in patients already receiving the drugs at the time of study entry.

In clinical studies, serum chemistry was evaluated at baseline and monthly. Hematology was evaluated at baseline, monthly for 6 months, and then every 3 months. Thyroid function was measured at baseline and every 6 months.

Other clinically relevant adverse reactions observed at <2% difference from AVONEX or placebo in controlled trials included abnormal liver function test, colitis, decreased lymphocyte count, diarrhea, dry skin, erythema, folliculitis, increased hepatic enzyme, laryngitis, lymphadenopathy, pneumonia, pruritus, psoriasis, respiratory tract infection, skin exfoliation, toxic skin eruption, vasculitis and viral infection.

6.2 Immunogenicity

As with all therapeutic proteins, there is potential for immunogenicity. In Study 1, patients were tested for anti-drug (daclizumab) antibodies at Week 4 and approximately every 3 months thereafter. Anti-drug antibodies and neutralizing antibodies were observed in 19% (175/913) and 8% (71/913) of patients, respectively. Anti-drug antibody responses were transient in 12% (110/913) of patients and persistent in 7% (65/913) of patients. Anti-drug and neutralizing antibody responses predominantly occurred during the first year of treatment, and their frequency declined with continued ZINBRYTA treatment.

In patients with neutralizing antibodies, daclizumab clearance was increased on average by 19% [see Clinical Pharmacology (12.3)]. There was no apparent correlation of anti-drug antibody or neutralizing antibody development to clinical response, adverse reactions, or pharmacodynamic profile of ZINBRYTA.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to daclizumab with the incidence of antibodies to other products may be misleading.

7.1 Hepatotoxic Drugs

Caution should be used when using hepatotoxic drugs, including non-prescription products, concomitantly with ZINBRYTA. Carefully consider the need for the use of herbal products or dietary supplements that can cause hepatotoxicity [see Warnings and Precautions (5.1)].

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

Safety and effectiveness of ZINBRYTA in patients less than 17 years old have not been established. Use of ZINBRYTA is not recommended in pediatric patients due to the risks of hepatic injury and immune-mediated disorders [see Warnings and Precautions (5.1, 5.2)].

8.5 Geriatric Use

Clinical studies of ZINBRYTA did not include a sufficient number of patients aged 65 and over to determine whether they respond differently than younger patients.

8.6 Hepatic Impairment

Clinical trials did not include patients with ALT or AST more than two times the ULN. Patients with signs and symptoms of hepatic impairment may be at increased risk for hepatotoxicity from ZINBRYTA [see Dosage and Administration (2.3, 2.4), Contraindications (4), and Warnings and Precautions (5.1)].

12.1 Mechanism of Action

The precise mechanism by which daclizumab exerts therapeutic effects in multiple sclerosis is unknown but is presumed to involve modulation of IL-2 mediated activation of lymphocytes through binding to CD25, a subunit of the high-affinity IL-2 receptor.

12.2 Pharmacodynamics

During ZINBRYTA treatment, mean cell counts for the major immune subsets (T, B, and NK cells) remained within normal ranges. Total lymphocyte, T and B cell counts decreased less than 10% from baseline during the first year of treatment. Total lymphocyte counts returned to baseline levels approximately 8-12 weeks after the last dose of ZINBRYTA (150 mg).

12.3 Pharmacokinetics

The pharmacokinetics of ZINBRYTA are similar for healthy volunteers and patients with multiple sclerosis (MS).

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

13.2 Animal Toxicology and/or Pharmacology

There was a dose-dependent increase in microglial aggregates in the brain and spinal cord of monkeys at subcutaneous doses greater than 10 mg/kg administered biweekly for up to 39 weeks. Microglial aggregates were, in some animals, associated with microhemorrhage; however, no evidence of neuronal injury was observed. There was evidence of reversibility by 12 weeks after the last dose.

Study 1: Active-Controlled Trial in RMS

Study 1 compared ZINBRYTA to 30 mcg weekly intramuscular doses of AVONEX in 1841 patients. The study included RMS patients who had either: 1) at least 2 relapses during the prior 3 years and at least one relapse in the year prior to randomization; or 2) one or more clinical relapses and one or more new T1 gadolinium (Gd)-enhancing or T2 hyperintense MRI lesions within the prior 2 years with at least one of these events in the prior 12 months. Patients with progressive forms of multiple sclerosis or an Expanded Disability Status Scale (EDSS) score greater than 5 were excluded. Treatment continued for up to 144 weeks until the last enrolled patient completed 96 weeks of treatment. Clinical assessments were to occur every 12 weeks and after relapse events. MRI scans were performed at Week 24 and Week 96.

The primary outcome measure of Study 1 was the annualized relapse rate (ARR). Additional outcome measures included the proportion of patients relapsed, the proportion of patients who experienced confirmed disability progression, and the number of new or newly enlarging T2 hyperintense lesions. Confirmed disability progression was defined as at least a 1 point increase from baseline EDSS (1.5 point increase for patients with baseline EDSS of 0) sustained for 12 weeks.

In Study 1, randomization assigned 919 patients to ZINBRYTA and 922 patients to AVONEX; 71% of ZINBRYTA- and 70% of AVONEX-treated patients completed at least 96 weeks of treatment with the assigned drug. At baseline, the mean age of patients was 36 years, the mean disease duration since diagnosis was 4.2 years, the mean EDSS score was 2.5, and the mean number of relapses in the prior year was 1.6. At baseline, 68% of patients were female, 46% of patients had MRI scans with T1 Gd-enhancing lesions and 41% of patients had previously taken one or more non-steroid treatments for MS.

ZINBRYTA had a statistically significant effect on the annualized relapse rate and on the number of new or newly enlarging T2 hyperintense lesions. There was no statistically significant effect on 12-week confirmed disability progression.

Results for Study 1 are shown in Table 4 and Figure 1, below.

Figure 1: Study 1 Percentage of Relapse-Free Patients

In a subgroup analysis of Study 1, a reduction was observed compared with AVONEX on annualized relapse rate across patient subgroups (based on gender, age, prior multiple sclerosis disease modifying therapy, and disease activity levels).

Study 2: Placebo-Controlled Trial in RMS

Study 2 compared ZINBRYTA to placebo in 412 patients. The study included RMS patients who had experienced at least one relapse in the year prior to randomization or who had one or more T1 Gd-enhancing MRI lesions within 6 weeks of randomization. Patients with progressive forms of multiple sclerosis or an EDSS score greater than 5 were excluded. Treatment duration was 52 weeks. Clinical assessments were to occur every 12 weeks and after relapse events. MRI scans were performed at weeks 24, 36, and 52 in all patients and every 4 weeks in a subset of patients.

The primary outcome measure of Study 2 was the annualized relapse rate (ARR) at Week 52. Additional outcome measures included new T1 Gd-enhancing lesions between Week 8 and Week 24, the proportion of patients relapsed, the proportion of patients who experienced 12-week confirmed disability progression (as defined in Study 1) and the number of new or newly enlarging T2 hyperintense lesions.

In Study 2, randomization assigned 208 patients to receive ZINBRYTA (150 mg) and 204 patients to receive placebo; 91% of ZINBRYTA patients and 91% of placebo patients completed treatment. At baseline, the mean age of patients was 36 years, the mean disease duration since diagnosis was 4.3 years, the mean EDSS score was 2.8, and the mean number of relapses in the prior year was 1.4. At baseline, 65% of patients were female, 48% of patients had MRI scans with T1 Gd-enhancing lesions and 21% of patients had previously taken one or more non-steroid treatments for MS.

ZINBRYTA had a statistically significant effect on the annualized relapse rate, the proportion of patients relapse free, the number of new T1 Gd-enhancing lesions, and the number of new or newly enlarging T2 hyperintense lesions. The results for Study 2 are shown in Table 5.

16.1 How Supplied

ZINBRYTA injection is a sterile, colorless to slightly yellow, clear to slightly opalescent solution for subcutaneous injection. ZINBRYTA is provided in a 29 gauge, 0.5 inch staked (pre-affixed) needle syringe with a rubber plunger stopper and rigid needle shield that are not made with natural rubber latex.

Two presentations are provided for ZINBRYTA injection, a single-dose prefilled autoinjector and a single-dose prefilled syringe.

16.2 Storage and Handling

Store in a refrigerator between 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or expose to temperatures above 30°C (86°F). Discard if frozen.

If refrigeration is unavailable, ZINBRYTA may be stored protected from light up to 30°C (86°F) for a period up to 30 days. Do not place ZINBRYTA back into the refrigerator after allowing it to warm to room temperature. Discard after 30 days without refrigeration.

16.3 Instructions for Disposal

Dispose in a sharps container or other hard plastic or metal sealable container. Always follow local regulations for disposal.

Hepatic Injury

Inform the patient of the risk of severe hepatic injury associated with ZINBRYTA. Advise patients of the symptoms of hepatic dysfunction, and instruct patients to report such symptoms to their health care provider immediately [see Warnings and Precautions (5.1)].

Discuss with the patient the importance of measuring hepatic laboratory values and having them evaluated by the health care provider monthly while taking ZINBRYTA and for up to 6 months after the last dose of ZINBRYTA.

Discuss with the patient the risk of concomitant use of other hepatotoxic medications, over the counter medications, herbal products, or dietary supplements.

Inform the patient that they will be given a ZINBRYTA Patient Wallet Card that they should carry with them at all times. This card describes symptoms which, if experienced, should prompt the patient to immediately seek medical evaluation.

Advise the patient to show the ZINBRYTA Patient Wallet Card to other treating health care providers.

Immune-Mediated Disorders

Advise patients that ZINBRYTA can cause their immune system to attack healthy cells in their body and that this can affect not only the liver but any organ system.

Skin Reactions

Advise patients that ZINBRYTA can cause dermatologic reactions that can range from mild rashes to serious reactions that could require treatment with other medications or result in hospitalization. Instruct patients to seek immediate medical attention if dermatologic reactions occur [see Warnings and Precautions (5.2)].

Lymphadenopathy

Inform patients that ZINBRYTA may cause lymphadenopathy that can range from mild events that can resolve on their own to serious lymphadenopathy that may require invasive procedures for diagnosis. Inform patients of the symptoms and instruct patients to contact their health care provider if they develop lymphadenopathy [see Warnings and Precautions (5.2)].

Autoimmune Hemolytic Anemia

Inform patients that ZINBRYTA may cause autoimmune hemolytic anemia that may be serious and could require blood transfusions and additional treatment. Advise patients of the symptoms of autoimmune hemolytic anemia and instruct patients to promptly contact their healthcare provider if they experience these symptoms [see Warnings and Precautions (5.2)].

Immune-mediated Colitis

Inform patients that ZINBRYTA may cause gastrointestinal reactions that may be serious and could require treatment. Advise patients of the symptoms of colitis and instruct patients to promptly contact their healthcare provider if they experience these symptoms [see Warnings and Precautions (5.2)].

ZINBRYTA REMS Program

ZINBRYTA is available only through a restricted program called the ZINBRYTA REMS Program [see Warnings and Precautions (5.3)]. Inform the patient of the following notable requirements:

• Patients must enroll in the program and comply with ongoing monitoring requirements [see Warnings and Precautions (5.1, 5.2)].

ZINBRYTA is available only from certified pharmacies participating in the program. Therefore, provide patients with the telephone number and website for information on how to obtain the product.

Allergic Reactions and Anaphylaxis

Advise patients of the symptoms of allergic reactions and anaphylaxis, and instruct patients to

seek immediate medical attention if these symptoms occur [see Warnings and Precautions (5.4)].

Risk of Infections

Inform patients that they may be more likely to get infections when taking ZINBRYTA, and that they should contact their health care provider if they develop symptoms of infection [see Warnings and Precautions (5.5)].

Depression and Suicide

Advise patients of the symptoms of depression and suicidal ideation as they have occurred with the use of ZINBRYTA and instruct patients to report symptoms of depression or thoughts of suicide to their health care provider immediately [see Warnings and Precautions (5.6)].

Instructions for Self-Injection Technique and Procedures

Provide appropriate instruction for methods of self-injection, including careful review of the ZINBRYTA Instructions for Use. Instruct the patient in the use of aseptic technique when administering ZINBRYTA.

Inform the patient that a health care provider should show them or their caregiver how to inject ZINBRYTA before administering the first dose. Tell the patient not to re-use needles, pens or syringes, and instruct the patient on safe disposal procedures. Inform the patient to dispose of used needles, pens and syringes in a puncture-resistant container.

46353-03

Manufactured by:
Biogen Inc.
Cambridge, MA 02142
U.S. License # 1697

Distributed by:
AbbVie Inc.
North Chicago, IL 60064

ZINBRYTA is a registered trademark of Biogen.
© 2016-2017 Biogen